Rapamycin (Sirolimus)
OtherAlso known as Sirolimus
Evidence tier
Substantial published literature
12,874 publications over 51 years · trials not yet curated
- Researched since
- 1975
- Publications
- 13k
- Mean purity
- —
- Vendors listing
- 0
No indexed vendor publishes certificate records for Rapamycin (Sirolimus) that this index could read yet, so no purity comparison is possible.
Score breakdown
The score has two halves: the research base — how long the compound has been studied and how much has been published — and the quality of the evidence the market produces for it, aggregated across every vendor that carries it: assayed purity, lot-to-lot consistency, readable third-party certificates and those vendors’ review record. It measures the evidence base, not the merits or safety of the substance.
Studied since 1975 — 51 years of published research
How long the compound has been studied. Fifteen years or more of published literature earns full marks; a newer compound earns less.
12,874 publications indexed in PubMed
The volume of published literature located. Full marks at fifty or more publications.
No certificate records indexed yet — nothing recorded yet
Average assayed purity on the certificates published by vendors that carry this compound. Full marks at 99.5%+, nothing at 95% or below.
No certificate records indexed yet — nothing recorded yet
How tightly assayed purity and labeled-versus-actual mass hold across different lots. Rewards reproducible manufacturing.
No vendor testing policy recorded yet — nothing recorded yet
Whether the vendors carrying this compound publish per-lot certificates anyone can read without an account.
No certificate records indexed yet — nothing recorded yet
Share of certificates issued by a recognised third-party testing lab rather than an unnamed or self-named one.
What is Rapamycin (Sirolimus)?
Rapamycin (sirolimus), a macrolide inhibitor of the mTOR pathway. It is an approved prescription medicine and one of the most-studied compounds in ageing and longevity research.
Studied in published research for ageing and longevity, as an mTOR inhibitor.
Regulatory status
Sirolimus is an approved prescription medicine in one or more of the United States, United Kingdom and European Union. When listed by the vendors in this index it is labeled for laboratory research use only, and nothing here is medical advice or an endorsement of human use.
What the research examines
The areas of published research this compound appears in. These describe what the literature has studied — never a claim of benefit, effect or suitability for any use.
Published research
PepIndex records the size and shape of the published research footprint only. It does not evaluate or summarise clinical significance, does not describe administration, and nothing here is a claim of safety or efficacy.
- Sirolimus (Rapamycin) for Slow-Flow Malformations in Children: The Observational-Phase Randomized Clinical PERFORMUS Trial — JAMA dermatology (2021)
Peer-reviewed article indexed in PubMed, published in JAMA dermatology (2021).
- Rapamycin (sirolimus, rapamune) — Current opinion in nephrology and hypertension (1995)
Peer-reviewed article indexed in PubMed, published in Current opinion in nephrology and hypertension (1995).
- Sirolimus — PubMed-indexed journal (2012)
Peer-reviewed article indexed in PubMed, published in PubMed-indexed journal (2012).
- Sirolimus — PubMed-indexed journal (2006)
Peer-reviewed article indexed in PubMed, published in PubMed-indexed journal (2006).
- Sirolimus — American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists (2022)
Peer-reviewed article indexed in PubMed, published in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists (2022).
- Rapamycin (sirolimus): a two-edged sword? — Journal of molecular and cellular cardiology (2006)
Peer-reviewed article indexed in PubMed, published in Journal of molecular and cellular cardiology (2006).
PepIndex describes what literature exists. We do not interpret it, assess clinical significance, or publish quantities, protocols or instructions for use.
Vendor comparison
| Vendor | Score here | Price / mg | Certificates | Mean purity | Label deviation | Get it |
|---|
Certificate records
No certificate records are indexed. Either none are published, or those published could not be read without an account.